Who responded?
The waterfall answers the headline question, but not when the response appeared or how long it lasted.
SignalFrame Synthetic-data experienceEARLY ONCOLOGY EVIDENCE EXPLORER
One endpoint.
Different patient stories.
Explore how dose, safety, response timing and biomarkers can tell different stories inside the same small cancer trial.
What this demonstrates
A response rate summarizes the cohort. It does not explain how the evidence developed patient by patient.
COHORT SF-741
Evidence at a glance
Objective responses
2/1217% of cohortPatients with toxicity
2Illustrative eventMedian follow-up
150daysPATIENTDAYS FROM FIRST DOSE
0122243
P01
-4%
P02
+19%
P03
-54%
P04
+37%
P05
-32%
P06
+37%
P07
+10%
P08
-17%
P09
+1%
P10
+3%
P11
+27%
P12
+43%
ResponseToxicityOn treatment
01
The cohort-level number is only the headline. Timing, durability, dose and tolerability determine what the headline can actually support.
FROM ENDPOINT TO EVIDENCE
The question changes when the clocks are aligned.
SignalFrame is an educational demonstration of the patient-level views OncoMetrika can build around a defined oncology evidence question.
What happened first?
Patient timelines connect dosing, biological change, imaging and safety without pretending they share one clock.
What can the cohort support?
Integrated views help teams separate a promising pattern from a claim the available data cannot yet carry.
ONCOLOGY EVIDENCE SPRINT
Have one difficult question hiding inside your data?
OncoMetrika turns one clearly scoped cancer research question into a review-ready analytical package using de-identified data.
Discuss an Evidence Sprint